Woodline Partners’s Upstream Bio UPB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$4.38M Hold
831,481
– – 0.01% 748
2026
Q2
$5.75M Hold
831,481
– – 0.02% 657
2026
Q1
$7.48M Buy
831,481
+71,229
+9% +$1.28M 0.03% 579
2025
Q4
$20.6M Buy
760,252
+158,000
+26% +$3.93M 0.08% 305
2025
Q3
$11.3M Buy
602,252
+44,000
+8% +$684K 0.05% 415
2025
Q2
$6.13M Buy
558,252
+1,189
+0.2% +$11K 0.03% 523
2025
Q1
$3.41M Buy
557,063
+30,552
+6% +$292K 0.02% 589
2024
Q4
$8.66M Buy
+526,511
New +$11.8M 0.06% 379

Other funds holding UPB

Woodline Partners's UPB Position: Q3 2026 in Review

Woodline Partners held its Upstream Bio (UPB) position steady in Q3 2026 at 831,481 shares worth $4.38M. The position accounts for 0.01% of the portfolio, ranked #748.

Woodline Partners first reported a position in UPB in Q4 2024 and has held it in 8 quarters since. The position peaked at $20.6M in Q4 2025. 135 funds tracked by Wall St. Rank hold UPB as of Q3 2026.

  • Woodline Partners held 831,481 shares of Upstream Bio worth $4.38M as of Q3 2026.
  • Woodline Partners left its Upstream Bio share count unchanged in Q3 2026.
  • Upstream Bio made up 0.01% of Woodline Partners's portfolio in Q3 2026, its #748 holding.
  • Woodline Partners first reported a position in Upstream Bio in Q4 2024 and has held it in 8 quarters since.
  • Woodline Partners's Upstream Bio position peaked at $20.6M in Q4 2025.
  • 135 funds tracked by Wall St. Rank held Upstream Bio as of Q3 2026.

Based on Woodline Partners's 13F filing for Q3 2026, filed 16 Nov 2026.